Foresee Pharmaceuticals Statistics

Total Valuation

Foresee Pharmaceuticals has a market cap or net worth of TWD 10.87 billion. The enterprise value is 10.12 billion.

Market Cap	10.87B
Enterprise Value	10.12B

Important Dates

The last earnings date was Monday, November 11, 2024.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	n/a

Share Statistics

Foresee Pharmaceuticals has 136.78 million shares outstanding. The number of shares has increased by 14.84% in one year.

Current Share Class	n/a
Shares Outstanding	136.78M
Shares Change (YoY)	+14.84%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	2.88%
Owned by Institutions (%)	2.70%
Float	109.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	33.03
PB Ratio	10.81
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-11.78
EV / Sales	30.93
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-12.28

Financial Position

The company has a current ratio of 2.67, with a Debt / Equity ratio of 0.22.

Current Ratio	2.67
Quick Ratio	2.10
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	-0.27
Interest Coverage	-174.81

Financial Efficiency

Return on equity (ROE) is -61.48% and return on invested capital (ROIC) is -34.11%.

Return on Equity (ROE)	-61.48%
Return on Assets (ROA)	-27.45%
Return on Capital (ROIC)	-34.11%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.17
Inventory Turnover	1.16

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -9.72% in the last 52 weeks. The beta is 1.11, so Foresee Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.11
52-Week Price Change	-9.72%
50-Day Moving Average	79.04
200-Day Moving Average	88.27
Relative Strength Index (RSI)	45.34
Average Volume (20 Days)	92,454

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Foresee Pharmaceuticals had revenue of TWD 327.18 million and -859.00 million in losses. Loss per share was -6.32.

Revenue	327.18M
Gross Profit	163.53M
Operating Income	-859.18M
Pretax Income	-807.34M
Net Income	-859.00M
EBITDA	-797.67M
EBIT	-859.18M
Loss Per Share	-6.32

Full Income Statement

Balance Sheet

The company has 972.76 million in cash and 219.72 million in debt, giving a net cash position of 753.04 million or 5.51 per share.

Cash & Cash Equivalents	972.76M
Total Debt	219.72M
Net Cash	753.04M
Net Cash Per Share	5.51
Equity (Book Value)	1.00B
Book Value Per Share	7.36
Working Capital	835.42M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -771.87 million and capital expenditures -52.39 million, giving a free cash flow of -824.27 million.

Operating Cash Flow	-771.87M
Capital Expenditures	-52.39M
Free Cash Flow	-824.27M
FCF Per Share	-6.03

Full Cash Flow Statement

Margins

Gross margin is 49.98%, with operating and profit margins of -262.60% and -262.54%.

Gross Margin	49.98%
Operating Margin	-262.60%
Pretax Margin	-246.76%
Profit Margin	-262.54%
EBITDA Margin	-243.80%
EBIT Margin	-262.60%
FCF Margin	-251.93%

Dividends & Yields

Foresee Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.84%
Shareholder Yield	-14.84%
Earnings Yield	-7.95%
FCF Yield	-7.58%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Foresee Pharmaceuticals has an Altman Z-Score of 6.82.

Altman Z-Score	6.82
Piotroski F-Score	n/a